Piroxicam

Piroxicam (CP-16171) is a non-steroidal anti-inflammatory drugs, acts as a COX inhibitor, with IC₅₀s of 47, 25 μM for human monocyte COX-1 and COX-2, respectively. IC50 & Target: IC50: 47 μM (COX-1, in human monocytes), 25 μM (COX-2, human monocytes)^[1] In Vitro: Piroxicam (CP-16171) is a non-steroidal anti-inflammatory drugs, acts as a COX inhibitor, with IC₅₀s of 47, 25 μM for human monocyte COX-1 and COX-2, respectively^[1]. Piroxicam (CP-16171) (167, 333, 500 μM) decreases cell population of T24 and the 5637 cells. Piroxicam (CP-16171) (500 μM) also reduces the cell viability of T24 and 5637 cell, and is significantly effective when combined with 0.05 μM carboplatin. The combination also inhibits Ki-67 expression in booth cells^[3]. In Vivo: Piroxicam (CP-16171) (0.3 mg/kg qd 24-h p.o.) reduces tumor volume in 12 of 18 dogs, and such and effect is via induction of apoptosis and reduction in urine basic fibroblast growth factor concentration^[2].